Novavax, Inc. (NVAX) — closed signal from February 17, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 18, 2026.
Predicted vs. what happened
What happened
Reached its target in 9 days.
The thesis — published February 17, 2026
Pfizer's deal to use Novavax's Matrix-M gives the company real validation and potential future payments, which can attract traders. The stock sits where many traders are betting against it, so positive news can push the price sharply higher. This is a short-term, speculative trade over the next 0-3 months, and it's exposed to policy and legal headlines that can make the price swing a lot.
Primary drivers
- Pfizer deal validates Novavax's vaccine tech and could lead to future payments
- High short interest means positive news can push the price up quickly
- If vaccine policy becomes clearer, investor mood toward biotech could improve
- This is a short-term trade with clear sizing and a limited risk area to protect capital
How it played out
NVAX: target reached in 9 days
Lyra published NVAX on 2026-02-17 at $8.74 as a short-term trade. The expected growth was 15%, with a target of $10.05. The thesis pointed to Pfizer's Matrix-M deal as validation for Novavax, possible future payments, high short interest, clearer vaccine policy, and a defined risk area.
Inside the window from 2026-02-17 to 2026-05-18, the stock reached $11.97 on 2026-02-26. That was above the target, with a peak gain of 37%, and it got there in 9 days. It ended the window at $8.93. The thesis played out early.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.